The estimated Net Worth of Peter P. Pfreundschuh is at least $732 millier dollars as of 21 February 2024. Mr Pfreundschuh owns over 3,764 units of Frequency Therapeutics Inc stock worth over $52,701 and over the last 11 years he sold FREQ stock worth over $144,666. In addition, he makes $535,000 as Chief Financial Officer at Frequency Therapeutics Inc.
Sign up
Mr Pfreundschuh FREQ stock SEC Form 4 insiders trading
Mr has made over 14 trades of the Frequency Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,764 units of FREQ stock worth $28,079 on 21 February 2024.
The largest trade he's ever made was exercising 15,000 units of Frequency Therapeutics Inc stock on 14 February 2022 worth over $4,500. On average, Mr trades about 1,728 units every 53 days since 2013. As of 21 February 2024 he still owns at least 175,669 units of Frequency Therapeutics Inc stock.
You can see the complete history of Mr Pfreundschuh stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Peter P. Pfreundschuh biography
Peter P. Pfreundschuh is the Chief Financial Officer at Frequency Therapeutics Inc.
What is the salary of Mr Pfreundschuh?
As the Chief Financial Officer of Frequency Therapeutics Inc, the total compensation of Mr Pfreundschuh at Frequency Therapeutics Inc is $535,000. There are 5 executives at Frequency Therapeutics Inc getting paid more, with David Lucchino having the highest compensation of $7,364,600.
How old is Mr Pfreundschuh?
Mr Pfreundschuh is 52, he's been the Chief Financial Officer of Frequency Therapeutics Inc since . There are 8 older and 8 younger executives at Frequency Therapeutics Inc. The oldest executive at Frequency Therapeutics Inc is Timothy Barberich, 72, who is the Independent Director.
What's Mr Pfreundschuh's mailing address?
Peter's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Insiders trading at Frequency Therapeutics Inc
Over the last 5 years, insiders at Frequency Therapeutics Inc have traded over $11,017,122 worth of Frequency Therapeutics Inc stock and bought 369,233 units worth $5,339,982 . The most active insiders traders include Joel S Marcus, Robert Langer et Marc A Cohen. On average, Frequency Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,858. The most recent stock trade was executed by Richard J. Mitrano on 18 August 2023, trading 464 units of FREQ stock currently worth $269.
What does Frequency Therapeutics Inc do?
frequency therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. through the controlled activation of progenitor cells, frequency enables disease modification without the complexity of genetic engineering. our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the u.s. alone.
What does Frequency Therapeutics Inc's logo look like?
Complete history of Mr Pfreundschuh stock trades at Immunomedics, UroGen Pharma Ltd, Voyager Therapeutics Inc, Y-Mabs Therapeutics Inc et Frequency Therapeutics Inc
Frequency Therapeutics Inc executives and stock owners
Frequency Therapeutics Inc executives and other stock owners filed with the SEC include:
-
David Lucchino,
President, Chief Executive Officer, Co-Founder, Director -
Christopher Loose,
Co-Founder, Chief Scientific Officer -
Carl LeBel,
Chief Development Officer -
David L. Lucchino,
Co-Founder, Pres, CEO & Director -
Wendy S. Arnold,
Chief People Officer -
Peter P. Pfreundschuh,
Chief Financial Officer -
Robert Langer,
Independent Director -
Marc Cohen,
Lead Independent Chairman of the Board Director -
Joel Marcus,
Independent Director -
Michael Huang,
Independent Director -
Timothy Barberich,
Independent Director -
Carlo Tanzi,
IR Contact Officer -
Cynthia Feldmann,
Independent Director -
Dana Hilt,
Chief Medical Officer -
Ajay Rai,
Vice President - Business Development -
Richard Mitrano,
Vice President of Finance and Operations -
Wendy Arnold,
Chief People Officer -
William Mclean,
Co-Founder, Vice President - Biology and Regenerative Medicine -
Dr. Carl P. LeBel,
Chief Devel. Officer -
Dr. Christopher R. Loose,
CoÂ-Founder & Chief Scientific Officer -
Dr. William W. Chin M.D.,
Sr. VP of Translational Medicine -
Dr. Dana C. Hilt,
Chief Medical Officer -
Dr. Jeff Hrkach,
Sr. VP of Technology Devel. -
Richard J. Mitrano,
VP of Fin. & Operations -
William J. McLean Ph.D.,
Co-founder & Sr. VP of Hearing Biology and Translational Research -
Quentin Mc Cubbin,
Chief Manufacturing Officer -
James E Deerfield Mgmt L.P....,
-
Peter P. Pfreundschuh,
Chief Financial Officer -
Michael Bookman,
General Counsel and Secretary